Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Weber

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Thalidomide and its derivatives: new promise for multiple myelomaDonna Weber
Medical Oncology (Northwood, London, England)|March 10, 2010
Advances in treatment for relapses and refractory multiple myelomaTiffany Richards, Donna Weber
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|February 23, 2002
Implementation of PET scan as a new servicePat Stanfill, Donna Weber
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|June 8, 2004
Evaluating technology for acquisitionPat Stanfill Edens, Donna Weber
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Treatment of plasma cell dyscrasias with thalidomide and its derivativesMeletios A Dimopoulos, Athanasios Anagnostopoulos, Donna Weber
Bone Marrow Research|June 8, 2012
Curability of multiple myelomaRaymond Alexanian, Kay Delasalle, Michael Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Thalidomide alone or with dexamethasone for previously untreated multiple myelomaDonna Weber, Kim Rankin, Maria Gavino, et al.
British Journal of Haematology|June 5, 2003
Thalidomide and dexamethasone for resistant multiple myelomaAthanasios Anagnostopoulos, Donna Weber, Kim Rankin, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Cancer|March 29, 2002
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of boneRichard B Wilder, Chul S Ha, James D Cox, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Thalidomide and its derivatives: new promise for multiple myelomaDonna Weber
Medical Oncology (Northwood, London, England)|March 10, 2010
Advances in treatment for relapses and refractory multiple myelomaTiffany Richards, Donna Weber
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|February 23, 2002
Implementation of PET scan as a new servicePat Stanfill, Donna Weber
The Journal of Oncology Management : the Official Journal of the American College of Oncology Administrators|June 8, 2004
Evaluating technology for acquisitionPat Stanfill Edens, Donna Weber
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Treatment of plasma cell dyscrasias with thalidomide and its derivativesMeletios A Dimopoulos, Athanasios Anagnostopoulos, Donna Weber
Bone Marrow Research|June 8, 2012
Curability of multiple myelomaRaymond Alexanian, Kay Delasalle, Michael Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Thalidomide alone or with dexamethasone for previously untreated multiple myelomaDonna Weber, Kim Rankin, Maria Gavino, et al.
British Journal of Haematology|June 5, 2003
Thalidomide and dexamethasone for resistant multiple myelomaAthanasios Anagnostopoulos, Donna Weber, Kim Rankin, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Cancer|March 29, 2002
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of boneRichard B Wilder, Chul S Ha, James D Cox, et al.
Pageof 4